A blog by Stefan Oschmann, Chairman of the Executive Board and CEO of Merck
At Merck, we are determined to ensure that patients are better heard during every step of the drug development process. To us, listening to patients is about much more than clinical trials and capturing patient reported outcomes, vital as they are. We believe that involving patients in the drug development process shouldn’t stop there. What is just as important to us is a deeper appreciation of the challenges faced by both patients and their carers. After all, it’s this understanding of unmet needs that ultimately leads to better products and services for all those who are affected by the illnesses we aim to cure.
Read more
For The Chance To...
Millions of people wouldn't be here today if it wasn't for life-changing science. And many more wouldn't be living the...
Read more
Leem is publishing its foresight analysis to address tomorrow’s health challenges.
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.